Chronic PCSK9 inhibitor therapy leads to sustained improvements in endothelial function, arterial stiffness, and microvascular function-Reference-Cited by-同舟云学术

Chronic PCSK9 inhibitor therapy leads to sustained improvements in endothelial function, arterial stiffness, and microvascular function

Published:2023-07 Issue: Volume:148 Page:104513
ISSN:0026-2862
Container-title:Microvascular Research
language:en
Short-container-title:Microvascular Research

Author:

Schremmer J.,Busch L.,Baasen S.,Heinen Y.,Sansone R.,Heiss C.,Kelm M.,Stern M.

Publisher

Elsevier BV

Subject

Cell Biology,Cardiology and Cardiovascular Medicine,Biochemistry

Reference46 articles.

1. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Münster (PROCAM) study;Assmann;Circulation,2002

2. The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis;Blum;Atherosclerosis,2009

3. Correlation of near infrared spectroscopy measurements of tissue oxygen saturation with transcutaneous pO2 in patients with chronic wounds;Bowen;SM Vasc. Med.,2016

4. PCSK9 in relation to coronary plaque inflammation: results of the ATHEROREMO-IVUS study;Cheng;Atherosclerosis,2016

5. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170000 participants in 26 randomised trials;Cholesterol Treatment Trialists;Lancet,2010

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A comprehensive retrospect on biomarkers indicating vascular failure;Vascular Failure;2024-12-01

2. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients Following Acute Coronary Syndromes: From Lipid Lowering and Plaque Stabilization to Improved Outcomes;Journal of Clinical Medicine;2024-08-25

3. Early Use of PCSK9 Inhibitors in the Prognosis of Patients with Acute Coronary Syndrome by Protecting Vascular Endothelial Function;Pharmacology;2024-07-17

4. Inhibition of proline‐rich tyrosine kinase 2 restores cardioprotection by remote ischaemic preconditioning in type 2 diabetes;British Journal of Pharmacology;2024-07-02

5. Emerging clinical role of proprotein convertase subtilisin/kexin type 9 inhibition–Part two: Current and emerging concepts in the clinical use of PCSK9 inhibition;European Journal of Clinical Investigation;2024-06-26